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Abstract
Background: Cytochrome P450 1B1 (CYP1B1) is active in the metabolism of estrogens to reactive
catechols and of different procarcinogens. Several studies have investigated the relationship
between genetic polymorphisms of CYP1B1 and breast cancer risk with inconsistent results. A G
→ C transversion polymorphism in the heme-binding region in codon 432 of the gene results in
amino acid change (Val → Leu); the Leu allele display increased catalytic efficiency for 4-
hydroxylation of estradiol in some experimental systems.
Methods: In this study, we utilized a polymerase chain reaction (PCR)-based restriction fragment
length polymorphism (RFLP) assay to assess the relationship between this polymorphism and
breast cancer risk in a case control study including 250 women with breast cancer and 250 controls
from four University Teaching Hospitals in Southern Nigeria.
Results: Heterozygosity for the CYP1B1 M1 genotype (CYP1B1 M1 [Val/Leu]) was associated with
a significant 59% increased risk of breast cancer (OR = 1.59, 95% CI 1.01–2.58) while homozygosity
for the genotype (CYP1B1 M1 [Leu/Leu]) conferred a non-significant 51% increased risk of breast
cancer. These risk profiles were modified in subgroup analysis. In premenopausal women,
harboring at least one CYP1B1 (Leu) allele conferred a significant two-fold increased risk of breast
from Second Annual International African-Caribbean Cancer Consortium Conference
Miami, FL, USA. 12–13 May 2008
Published: 10 February 2009
Infectious Agents and Cancer 2009, 4(Suppl 1):S12 doi:10.1186/1750-9378-4-S1-S12
<supplement> <title> <p>Second Annual International African-Caribbean Cancer Consortium Conference</p> </title> <editor>Camille Ragin and Emanuela Taioli</editor> <sponsor> <note>Publication supported in part by the University Of Pittsburgh Graduate School Of Public Health, the University of Pittsburgh Cancer Institute, and by the National Institute of Health, grant number R13CA130596A.</note> </sponsor> <note>Proceedings</note> <url>http://www.biomedcentral.com/content/pdf/1750-9378-4-S1-info.pdf</url> </supplement>
This article is available from: http://www.infectagentscancer.com/content/4/S1/S12
© 2009 Okobia et al; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Infectious Agents and Cancer 2009, 4(Suppl 1):S12 http://www.infectagentscancer.com/content/4/S1/S12
Page 2 of 8
(page number not for citation purposes)
cancer (OR = 2.04, 95% CI 1.10–3.78). No significant association was observed in postmenopausal
women (OR = 1.08, 95% CI 0.57–2.04).
Conclusion:  Our results suggest that the codon 432 polymorphism of the CYP1B1  gene is
associated with increased risk of breast cancer and is particularly involved in breast cancer risk in
premenopausal women of African descent.
Background
Breast cancer has unique racial/ethnic variations in inci-
dence and burden. While the incidence is rising globally,
the increase is occurring faster in population groups that
hitherto enjoyed low incidence. Reasons for the racial/
ethnic variation in breast cancer incidence are unclear;
however, differences in the distribution of polymor-
phisms in key candidate genes involved in estrogen/xeno-
biotic metabolism might contribute to variation in breast
cancer susceptibility in different populations. The CYP1B1
gene is located on chromosome 2p21-p22 and contains
three exons [1-3]. The entire coding sequence of the gene,
however, is contained in exons 2 and 3 [1-3]; exon 3
encodes the heme-binding region of the enzyme [4].
CYP1B1 might be involved in hormonal carcinogenesis
through its ability to catalyze the metabolism of estradiol
to 2-hydroxyestradiol and 4-hydroxyestradiol [5]. The
former metabolite is mainly produced in the liver whereas
significant amount of 4-hydroxyestradiol are formed in
extrahepatic tissues. Whereas 2-hydroxyestradiol has little
or no carcinogenic activity, 4-hydroxyestradiol and estro-
gen have been shown to be potent carcinogens in animal
models [6] and humans [7,8]. In-situ conjugation of this
metabolite by phase II enzymes is relatively low in extra-
hepatic tissues, thus leading to its accumulation. The car-
cinogenic activity of 4-hydroxyestradiol could be due to
its hormonal activity, which in some biological assays has
been shown to be even higher than the parent hormone.
In addition, 4-hydroxyestradiol can undergo redox cycling
[7] which results in the formation of free radicals such as
superoxide and in the generation of reactive semiqui-
none/quinone intermediates that have been shown to
damage biological target molecules such as DNA [8].
Six polymorphisms of the CYP1B1  gene have been
described in the Caucasian populations, of which four
results in amino acid substitutions [3,4]. Two of these
amino acid substitutions are located in exon 3, which
encodes the heme-binding domain: codon 432 Val → Leu
and 453 Asn → Ser [4] while two other amino acid substi-
tutions are found in codons 48 Arg → Gly and 119 Ala →
Ser in exon 2 [3]. The codon 432 Val → Leu polymor-
phism creates and Eco57I site. Several molecular epidemi-
ological studies have evaluated the association of
polymorphisms in CYP1B1 gene and breast cancer risk in
various populations, including seven in Caucasian [4,9-
14] and four in Asian populations [15-18]. There is scanty
data on the role of polymorphisms in this gene in breast
cancer susceptibility in populations of African descent.
Only one of the US studies recruited a small sample of
African-American women; there are no studies on sub-
Saharan African populations. Although, several polymor-
phisms have been described in the CYP1B1 gene, we have
chosen in this exploratory study to evaluate the role of the
CYP1B1 Val432Leu polymorphism in breast cancer sus-
ceptibility in Nigerian women since there is experimental
evidence suggesting that the variant CYP1B1 432Leu allele
exceeded the wild-type CYP1B1 432Val allele with respect
to estrogen hydroxylation activities. Given the carcino-
genic and estrogenic potential of 4-OH-E2, it is plausible
to speculate that inheritance of the CYP1B1 432Leu allele
may contribute to increased breast cancer risk associated
with estrogen-mediated carcinogenesis.
Materials and methods
Subjects
Study participants were recruited between September
2002 and April 2004 in four University Teaching Hospi-
tals in Southern Nigeria including University of Benin
Teaching Hospital, Benin City; Nnamdi Azikiwe Univer-
sity Teaching Hospital, Nnewi; University of Nigeria
Teaching Hospital, Enugu; and University of Port Har-
court Teaching Hospital, Port Harcourt. The Institutional
Review Board of University of Pittsburgh and the Ethics
and Research Committees of the Nigerian institutions
approved the study prior to commencement. A total of
500 study participants comprising 250 women with inci-
dent and prevalent breast cancer and 250 age- and institu-
tion-matched controls were recruited for the study.
Women with confirmed breast cancer were recruited dur-
ing surgical out-patient clinic visits or in-patient admis-
sions while control subjects with non-malignant surgical
diseases such as road traffic accident and other injuries (n
= 168), intestinal obstructions (n = 49), appendicitis/pel-
vic inflammatory disease (26), urolithiasis and urinary
tract infections (n = 5) and cholelithiasis (n = 2) were
recruited from the same hospitals. Exclusion criteria
include non-confirmation of diagnosis of breast cancer, a
diagnosis of other malignant diseases, and refusal of
donation of blood samples.
Prior to recruitment, participants signed informed con-
sent after detailed explanation of key points of the study
including study objectives, risks and benefits, confidenti-Infectious Agents and Cancer 2009, 4(Suppl 1):S12 http://www.infectagentscancer.com/content/4/S1/S12
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ality and the rights of participants. Interviewer-adminis-
tered questionnaires were used for data collection;
questions were designed to gather demographic history
including age, sex, religion, occupation, exposure to
chemical fertilizers and pesticides, and rearing of domes-
tic animals. In addition, obstetric and gynecological his-
tory including age at menarche, age at first full-term
pregnancy, parity, breastfeeding, age at menopause (for
postmenopausal subjects), history of use of hormonal
contraceptives and hormone replacement therapy and
surgical oophorectomy was obtained. Information about
lifestyle habits such as cigarette smoking and alcohol con-
sumption was also obtained from study participants.
Anthropometric measurements including height, weight,
waist and hip circumferences were taken at the end of the
interview.
Sample donation and preparation
Blood samples were collected at the end of the interview;
details are reported elsewhere [19,20]; 10 ml of whole
blood was collected in one 10 ml K3-EDTA vacutainer
tube from each of the study participants and stored in ice
packs until it was centrifuged within 10 h of collection
and buffy coats collected and stored in 3 ml tubes. All the
samples were stored at -20°C in the various study sites in
Nigeria and later transferred to the Nigerian coordinating
center at the University of Benin Teaching Hospital in
Polar Pack -20 C ice packs for frozen shipments and later
shipped to University of Pittsburgh in dry ice using
express services. Samples were stored at -80°C at the Uni-
versity of Pittsburgh until DNA extraction.
DNA extraction was carried out using QIAamp DNA Mini
Kits (for buffy coats) and QIAamp DNA Midi Kits (for
blood clots) protocols (QIAGEN Inc. Valencia, CA). The
extracted DNA was stored at 4°C until used for PCR and
RFLP analysis.
PCR and RFLP analysis
Genomic DNA from the cases and control subjects were
analyzed for the presence of the G to C transversion muta-
tion at codon 432 of the CYP1B1 gene by a PCR-based
Restriction Fragment Length Polymorphism (RFLP) assay.
PCR amplification of a 650 bp fragment of the CYP1B1
gene, including part of exon 3 that contains the polymor-
phism was carried out using forward primer: TCACTT-
GCTTTTCTCTCTCC and reverse primer:
AATTTCAGCTTGCCTCCTG. A 50 μl PCR reaction mixture
containing 2 μl of genomic DNA, 5 μl of deoxynucleotide
triphosphates, 5 μl each of forward and reverse primers, 5
μl of 10× buffer, 1.5 μl of MgCl2 and 0.5 μl of Taq
polymerase was placed in a thermalcycler. After denatur-
ing for 10 min at 95°C, the DNA was amplified for 35
cycles at 95°C for 60 s, 58°C for 60 s, and 72°C for 60 s,
followed by a 7 min extension at 72°C. A positive control
containing genomic DNA and a negative control contain-
ing everything except DNA were included in the PCR
experiment. Five μl of each PCR product, including the
controls, were verified on a 2% agarose gel to ensure that
the expected 650 bp product was generated.
Restriction digest for the DNA fragment was carried out
using Eco57I restriction enzyme. Fifteen μl of the PCR
product was digested for 16 h overnight at 37°C with 1
unit of Eco57I (New England Biolabs). The product of the
restriction digest was mixed with 10 μl of loading dye and
verified on a 3% agarose gel (with Ethidium bromide)
electrophoresis in a 1× Tris-Borate-EDTA buffer at 200 V
for 60 min. The presence of a G at position 1294
(CYP1B1-codon 432) generated a unique 650 bp frag-
ment, while the 650 bp fragment was divided into unique
340 bp and 310 bp fragments when position 1294 con-
tains a C. The gels were visualized by UV light and the
RFLP gel electrophoresis products were read by two inde-
pendent persons who were unaware of the identities of
samples as either cases or controls.
RFLP assays employing Eco57I restriction enzyme were
successful in 228 cases and 226 controls, therefore the
analysis is restricted to this sample of women.
Statistical analysis
Statistical analysis was carried out using the Statistical
Analysis System (SAS) software (Version 8.0). Condi-
tional logistic regression was used to assess the association
between the CYP1B1 genotypes and breast cancer risk in
the whole sample. Stratified analyses according to meno-
pausal status were carried out. Relevant risk factors that
were identified as significant predictors of breast cancer
risk were controlled for in the multivariate logistic regres-
sion models.
Results
Demographic characteristics
Five hundred participants comprising 250 women with
breast cancer and 250 age- and institution-matched con-
trols were recruited from four University Teaching Hospi-
tals in Midwestern and Southeastern Nigeria. However,
this report is based on data on 228 cases and 226 control
subjects in whom RFLP polymorphism assays on CYP1B1
gene were successful. Mean age of cases and control sub-
jects were similar (46.3 ± 11.72 years and 47.3 ± 12.14
years respectively). Using univariate logistic regression
models, the following variables including family history
of breast cancer, education, ever married, age at fullterm
pregnancy (FFTP), parity, duration of breastfeeding, abor-
tion, use of hormone contraceptives, waist/hip ratio, and
body mass index (BMI) were found to be significant pre-
dictors of breast cancer risk. However, only three variables
including Family history of breast cancer (OR = 11.17,Infectious Agents and Cancer 2009, 4(Suppl 1):S12 http://www.infectagentscancer.com/content/4/S1/S12
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95% CI 1.37–91.33), age at first fullterm pregnancy
greater than 20 years (OR = 1.32, 95% CI 1.17–3.41) and
waist/hip ratio (OR = 1.90, 95% CI 1.18–3.04) were sig-
nificant predictors of breast cancer risk in the final multi-
ple logistic regression model as shown in Table 1. More
details on distribution of anthropometric and reproduc-
tive variables and their association with breast cancer are
reported elsewhere [21,22].
Allele and genotype frequencies
All women
The CYP1B1 (Val) allele was less frequent in cases (0.86)
compared to control subjects (0.89). The distribution of
the CYP1B1 genotype is shown in Table 2. The genotype
frequencies of the CYP1B1 (Val/Val), CYP1B1 (Val/Leu)
and CYP1B1 (Leu/Leu) in the cases were 0.73, 0.25, and
0.02, respectively while the corresponding frequencies in
the control subjects were 0.81, 0.17, and 0.02, respec-
tively. The distribution of CYP1B1 (Val/Leu) alleles in the
control subjects was in Hardy-Weinberg equilibrium,
overall and in both premenopausal and postmenopausal
women.
Premenopausal women
Among 142 premenopausal breast cancer cases and 142
premenopausal control women, the RFLP polymorphism
assays were successful in 125 cases and 129 controls. The
CYP1B1 (Val) allele was less frequent among premeno-
pausal cases (0.85) compared to the control subjects
(0.92). As shown in Table 2, the CYP1B1 (Val/Leu) and
CYP1B1 (Leu/Leu) genotypes were more common in
cases compared with the control subjects.
Postmenopausal women
Of the 108 postmenopausal breast cancer cases and 108
postmenopausal control subjects, the PCR-based RFLP
assays were successful in 103 cases and 97 control sub-
jects. The distribution of the CYP1B1 (Val) and CYP1B1
(Leu) alleles in postmenopausal breast cancer cases and
controls were similar. There were slight differences in the
frequency of the CYP1B1  (Val/Val),  CYP1B1  (Val/Leu)
and CYP1B1 (Leu/Leu) genotypes among cases and con-
trol subjects, as shown in Table 2. All the three
homozygous variants were control subjects.
CYP1B1 genotypes and breast cancer risk
All women
As shown in Table 2, cases were more likely to harbor the
Leu allele than the controls. The heterozygous CYP1B1
(Val/Leu) genotype was associated with a significant
increased risk of breast cancer (Odds ratio [OR] = 1.59,
95% Confidence Interval [CI] 1.01–2.52), compared with
the homozygous wild type CYP1B1 (Val/Val) genotype.
There were very few study subjects with the homozygous
variant CYP1B1 (Leu/Leu), four among the cases and five
among the control subjects; this genotype was not associ-
ated with breast cancer (OR = 0.87, 95% CI 0.23–3.30).
Adjustment for waist/hip ratio (WHR) slightly attenuated
the risk associated with the CYP1B1 1B1 (Val/Leu) geno-
type in all women (OR = 1.57, 95% CI 0.99–2.51). The
risk associated with the CYP1B1 (Leu/Leu) (OR = 0.94,
95% CI 0.24–3.64) and the combined CYP1B1 (Val/Leu)
and CYP1B1 (Leu/Leu) genotypes (OR = 1.51, 95% CI
0.96–2.36) remained essentially unchanged.
Premenopausal women
The heterozygous CYP1B1 (Val/Leu) genotype was associ-
ated with a significantly increased risk of premenopausal
breast cancer (OR = 2.00, 95% 1.05–3.81; the risk associ-
ated with the homozygous genotype (Leu/Leu) did not
reach significance (OR = 2.40, 95% CI 0.43–13.38). The
risk of premenopausal breast cancer with the hetero-
zygous  CYP1B1  (Val/Leu) and homozygous CYP1B1
(Leu/Leu) genotypes combined was 2.04 (95% CI 1.10–
3.78) (Table 2). The risk of premenopausal breast cancer
associated with the CYP1B1 genotypes remained essen-
tially unchanged when WHR was included in the model.
Table 1: Multiple conditional logistic regression comparing cases and controls. Significant demographic predictors of breast cancer risk 
[Numbers (Percentages (%)], odds ratio (OR), 95% confidence interval (95% CI)
Variable Cases Controls OR 95% CI
Family history breast
Cancer
Yes 14 (6.00) 1 (0.40) 11.17 1.37, 91.33
No 214 (94.00) 225 (99.60) 1.00
Age at first fullterm
Pregnancy (>20 years)
Yes 162 (77.20) 136 (65.07) 1.32 1.17, 3.41
No 48 (22.8) 73 (34.93) 1.00
Waist/hip ratio (>0.90) Yes 147 (64.47) 107 (47.35) 1.90 1.18, 3.04
No 81 (35.53) 119 (52.65) 1.00Infectious Agents and Cancer 2009, 4(Suppl 1):S12 http://www.infectagentscancer.com/content/4/S1/S12
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Postmenopausal women
There was no association between the CYP1B1 polymor-
phism and breast cancer in post menopausal women.
Harboring at least one CYP1B1 (Leu) allele was not asso-
ciated with risk of breast cancer in postmenopausal
women (OR = 1.08, 95% CI 0.57–2.04). Controlling for
WHR did not significantly alter the risk profiles (Table 2).
Discussion
Breast cancer is a disease with unique phenotypic mani-
festations in different racial/population groups. It has
been hypothesized that these population-specific charac-
teristics of breast cancer may be partly due to differences
in genetic susceptibility to the disease arising from varia-
tion in the frequency of different polymorphic alleles of
key candidate genes involved in estrogen and xenobiotic
metabolism in different populations. Our study was
designed to evaluate the hypothesis that the CYP1B1
Val432Leu polymorphisms in the CYP1B1  gene, a key
candidate gene involved in phase I hydroxylation of estro-
gens (17β-estradiol and estrone) to 4-hydroxy catechols
might contribute to breast cancer risk in Nigerian women.
Comparison of our data with reports from other popula-
tions indicates wide variation in the distribution of the
CYP1B1 codon 432 Val → Leu polymorphism across dif-
ferent populations groups. The frequency of the CYP1B1
(Val) allele among control subjects in our study (0.89) is
closer to the frequency in African-Americans (0.70) [4]
but much higher than the figures reported in Caucasians
(0.42) [9], Asians in China (0.46) [18], Japan (0.15) [17],
and Korea (0.11) [16].
Table 2: Distribution of Cytochrome P4501B1 alleles and genotypes in relation to breast cancer risk
Cases Controls OR (95% CI) OR (95% CI)*
All women (n = 228) (n = 226)
Allele frequencies
CYP1B1(Val) 0.86 0.89
CYP1B1(Leu) 0.14 0.11
Genotype frequencies
CYP1B1 (Val/Val) 167 (47.85) 182 (52.15) 1.00
CYP1B1 (Val/Leu) 57 (59.38) 39 (40.62) 1.59 (1.01–2.52) 1.57 (0.99–2.51)
CYP1B1 (Leu/Leu) 4 (44.44) 5 (55.6) 0.87 (0.23–3.30) 0.94 (0.24–3.64)
CYP1B1 (Val/Val) 167 (47.85) 182 (52.15) 1.00
CYP1B1 (Val/Leu) + (Leu/Leu) 61 (58.10) 44 (41.90) 1.51 (0.92–2.35) 1.51 (0.96–2.36)
Pre-menopausal women (n = 125) (n = 129)
Allele frequencies
CYP1B1(Val) 0.85 0.92
CYP1B1(Leu) 0.15 0.08
Genotype frequencies
CYP1B1 (Val/Val) 91 (45.50) 109 (54.50) 1.00
CYP1B1 (Val/Leu) 30 (62.50) 18 (37.50) 2.00 (1.05–3.81) 1.97 (1.02–3.81)
CYP1B1 (Leu/Leu) 4 (66.67) 2 (33.33) 2.40 (0.43–13.38) 2.64 (0.46–15.23)
CYP1B1 (Val/Val) 91 (45.50) 109 (54.50) 1.00
CYP1B1 (Val/Leu) + (Leu/Leu) 34 (62.96) 20 (37.04) 2.04 (1.10–3.78) 2.04 (1.07–3.81)
Postmenopausal women (n = 103) (n = 97)
Allele frequencies
CYP1B1(Val) 0.87 0.86
CYP1B1(Leu) 0.13 0.14
Genotype frequencies
CYP1B1 (Val/Val) 76 (51.00) 73 (49.00) 1.00
CYP1B1 (Val/Leu) 27 (56.30) 21 (43.80) 1.24 (0.64–2.38) 1.20 (0.62–2.34)
CYP1B1 (Leu/Leu) 0 (0.00) 3 (100.00) ** **
CYP1B1 (Val/Val) 76 (51.00) 73 (49.00) 1.00
CYP1B1 (Val/Leu) + (Leu/Leu) 27 (52.94) 24 (47.06) 1.08 (0.57–2.04) 1.05 (0.55–2.01)
* Adjusted for waist/hip ratio (WHR)
** Odds ratios could not be determined due to missing values in some cellsInfectious Agents and Cancer 2009, 4(Suppl 1):S12 http://www.infectagentscancer.com/content/4/S1/S12
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Our results suggest that harboring one CYP1B1  (Leu)
allele was significantly associated with breast cancer (OR
= 1.59, 95% CI 1.01–2.52). Subgroup analysis based on
menopausal status showed that the risk conferred by this
polymorphism was essentially restricted to premenopau-
sal women in whom the combination of CYP1B1 (Val/
Leu) and CYP1B1  (Leu/Leu) genotypes was associated
with over 2-fold increased risk of breast cancer (OR =
2.04, 95% CI 1.10–3.78). This association was not con-
firmed in postmenopausal women. The associations were
not significantly modified by the adjustment of the data
for waist/hip ratio (a surrogate measure of etiologically
relevant obesity) in either premenopausal or postmeno-
pausal women, despite the finding of preferential 4-
hydroxylation of estrogens in obese women on high fat
diet [23].
Several other investigators have evaluated the relationship
between CYP1B1 polymorphisms and breast cancer in dif-
ferent populations. There appear to be no significant over-
all association between the CYP1B1 Val/Leu variant and
breast cancer risk in Caucasian populations in a recent
meta-analysis [24]. However, a pooled analysis suggests a
possible association of both the Val/Leu and Val/Val gen-
otypes with breast cancer in Caucasians but no significant
effect was observed in Asians or African-American subjects
[24]. Among the seven studies in Caucasians, three
reported no association between the CYP1B1 Val432Leu
polymorphism and breast cancer risk [4,10,14], while
three reported a risk effect for the valine allele [9,11,13];
one study reported an inverse association between the
valine allele and breast cancer [12]. Statistical significance
for the association between breast cancer and the CYP1B1
Val/Val polymorphism was reached in two studies
[11,13]. In one of these studies, Listgarten et al. [11]
found that harboring the heterozygous Val/Leu genotype
was associated with a 2.15-fold increased risk of breast
cancer (95% CI 1.31–3.52) while the homozygous
mutant (Leu/Leu) conferred a 3.30-fold increased risk
(95% CI 1.76–6.19). In the second study of 84 cases and
103 controls among the Turkish population, Kobacas et
al. [13] reported an overall association between carriers of
at least one Val allele and breast cancer risk among
women with body mass index (BMI) > 24 kg/m2 (OR =
2.81, 95% CI 1.38–3.74). Although Bailey et al. [4] failed
to demonstrate a significant association between the
CYP1B1 Val432Leu polymorphism and breast cancer risk,
they noted that Caucasian patients with the Val/Val geno-
type had a significantly higher percentage of breast cancer
that were positive for estrogen receptors (ERs) or proges-
terone receptors (PRs), suggesting that this polymorphism
may be functionally important for the expression of these
steroid receptors.
A small hospital-based case-control study involving 59
African-American women found no statistically signifi-
cant association between the CYP1B1  Val432Leu poly-
morphism and breast cancer risk [4]. Of three studies in
mixed U.S. populations [25-27], one [26] reported no sig-
nificant association, while two [25,27] reported an inverse
association between the Val/Val genotype and breast can-
cer (OR = 0.4, 95% CI 0.1–1.0 and OR = 0.7, 95% CI 0.6–
0.9, respectively) and for the Val/Val and Val/Leu geno-
types combined (OR = 0.4, 95% CI 0.1–1.0 and OR = 0.8,
95% CI 0.7–0.9, respectively). Meta-analysis of these stud-
ies in African-American and mixed populations showed
no overall significant risk associated with the CYP1B1
Val432Leu polymorphism in breast cancer susceptibility
in these populations [24].
Meta-analysis of studies on the association between
CYP1B1 Val432Leu polymorphism and breast cancer risk
failed to demonstrate an overall significant association in
Asian women [24]. Of the four available studies, three
[15,16,26] found no significant association. Only one
study in the Chinese population [18] reported that, com-
pared with those with the Val/Val genotype, women with
the Leu/Leu genotype had a 2.3-fold (95% CI 1.2–4.5)
elevated risk of breast cancer after adjusting for confound-
ing variables, the positive association between the Leu/
Leu genotype and breast cancer was more pronounced in
postmenopausal women (OR = 3.1, 95% CI 1.0–9.1) than
in premenopausal women (OR = 1.9, 95% CI 0.8–4.3).
The differences in breast cancer risk associated with the
CYP1B1 Val432Leu polymorphism in different popula-
tions may be due to several reasons including differences
in frequency of Val and Leu alleles in different popula-
tions, the relatively small sample size of some studies
[4,11,13,25,26], as well as differences in study designs.
The mechanisms through which polymorphisms in
CYP1B1 might influence breast cancer risk are not com-
pletely known. CYP1B1 is expressed constitutively in ext-
rahepatic tissues including lung and mammary tissue
[28]. Although other cytochrome P450 enzymes, such as
CYP1A2 and CYP3A4, are involved in hepatic and extrahe-
patic estrogen hydroxylation, CYP1A1 and CYP1B1 dis-
play the highest levels of expression in breast tissue [28];
CYP1B1 exceeds CYP1A1 in its catalytic efficiency as an
estradiol (E2) hydroxylase, and differs from CYP1A1 in its
main site of catalysis [5,29,30]. CYP1B1 has its primary
activity at the C-4 position of estradiol (E2), whereas
CYP1A1 has its primary activity at the C-2 position. These
two metabolites differ greatly in their carcinogenicity.
Treatment with 4-OH-E2, but not 2-OH-E2, induced renal
cancer in Syrian hamster [7,31]. Analysis of renal DNA
demonstrated that 4-OH-E2  significantly increased 8-
hydroxydeoxyguanosine levels, whereas 2-OH-E2 did notInfectious Agents and Cancer 2009, 4(Suppl 1):S12 http://www.infectagentscancer.com/content/4/S1/S12
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cause oxidative DNA damage [32]. Similarly, 4-OH-E2
induced DNA single-strand breaks whereas 2-OH-E2 had a
negligible effect [33]. Comparison of the corresponding
catechol estrogen quinones showed that E2-3,4-quinone
produced two to three orders of magnitude higher levels
of depurinating adducts than E2-2,3-quinone. Signifi-
cantly higher 4-OH-E2/2-OH-E2 ratios were observed in
breast tumor tissue than in adjacent normal breast tissue
[34]. These findings suggest a causative role of 4-OH cate-
chol estrogens in carcinogenesis and implicate CYP1B1 as
a key player in the process.
To the best of our knowledge, ours is the largest case-con-
trol study on CYP1B1  Val432Leu polymorphism and
breast cancer risk conducted in African populations.
The epidemiologic literature on determinants of breast
cancer in sub-Saharan African populations is scanty
despite the evidence that breast cancer is already a public
health problem in these developing countries [35,36] and
the burden of the disease is likely to increase as women in
these populations adopt Western diets and sedentary life-
styles. The use of hospital controls instead of population-
based controls might be a source of systematic bias; poor
research infrastructure including the absence of a popula-
tion-based cancer registry and lack of functional commu-
nication facilities limited our choice of recruitment for the
control subjects. Recruitment of incident and prevalent
cases of breast cancer may also be a source of systematic
bias as women with rapidly progressive forms of breast
cancer may have died early, leaving us with a subpopula-
tion of less aggressive prevalent cases. This is particularly
important given the report of an interaction between the
CYP1B1 Val → Leu polymorphism and hormone receptor
status noted in Caucasian women [4]. The observed pre-
ponderance of hormone receptor positive tumors in indi-
viduals harboring the Val/Val genotype would result in
selective survival advantage of this genotype. However,
such an interaction if present in our study population
would result in underestimation of the breast cancer risk
associated with the presence of the CYP1B1 (Leu) allele.
The non-availability of facilities for hormone receptor
assays during the recruitment of study participants in the
Nigerian study sites limited our ability to actually evaluate
the presence of such interaction if any.
Conclusion
This study has demonstrated a role for the CYP1B1 Val →
Leu polymorphism in premenopausal breast cancer risk in
Nigerian women. This polymorphism might be mediating
its effect through increased metabolic conversion of estra-
diol, the main estrogen in premenopausal women, to 4-
hydroxy estradiol and estrogen quinone and semiquinone
intermediates. The results we report in this study need to
be considered in conjunction with clinical and epidemio-
logical information. In fact, breast cancer is predomi-
nantly a premenopausal disease in Nigerian women [37],
with a disproportionately higher prevalence of hormone
receptor negative breast cancer, estimated at about 76%
[38]. These data, together with the observation of a higher
proportion of the CYP1B1 (Val) allele among postmeno-
pausal women with hormone receptor positive breast can-
cer [4], and of an association between Nigerian
premenopausal breast cancer and the CYP1B1 (Leu) allele
suggest that breast cancer in sub-Saharan African popula-
tions may have a different etiopathogenesis than in Cau-
casian or Asian populations. The understanding of
differences in estrogen and xenobiotic metabolism result-
ing from polymorphic variants in key candidate genes,
and their interaction with environmental exposure has
the potential to considerably improve our ability to char-
acterize individual risk of breast cancer and enhance our
ability to design individual and population-specific con-
trol and preventive measures.
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